IPCA Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹1900.60
Market cap
48,218 Cr
Stock P/E
36.7
P/B
5.06
Dividend yield
0.1%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,588 Cr | 3,619 Cr | 5,672 Cr | 7,705 Cr | 2,093 Cr | 4,448 Cr | 2,245 Cr | 2,247 Cr | 2,309 Cr | 2,557 Cr | 2,393 Cr | 2,388 Cr |
| Operating expenses (approx.) | 1,235 Cr | 2,907 Cr | 4,538 Cr | 6,367 Cr | 1,679 Cr | 3,566 Cr | 1,762 Cr | 1,997 Cr | 1,860 Cr | 2,042 Cr | 1,821 Cr | 1,857 Cr |
| EBITDA | 352 Cr | 712 Cr | 1,134 Cr | 1,338 Cr | 413 Cr | 881 Cr | 483 Cr | 250 Cr | 449 Cr | 515 Cr | 571 Cr | 532 Cr |
| OPM % | 22.2% | 19.7% | 20.0% | 17.4% | 19.8% | 19.8% | 21.5% | 11.1% | 19.5% | 20.1% | 23.9% | 22.3% |
| Other income | 45 Cr | 83 Cr | 106 Cr | 125 Cr | 21 Cr | 47 Cr | 20 Cr | 26 Cr | 33 Cr | 28 Cr | 20 Cr | 94 Cr |
| Interest | 31 Cr | 76 Cr | 109 Cr | 138 Cr | 24 Cr | 47 Cr | 17 Cr | 22 Cr | 19 Cr | 20 Cr | 18 Cr | 20 Cr |
| Depreciation | 69 Cr | 160 Cr | 259 Cr | 357 Cr | 99 Cr | 199 Cr | 98 Cr | 100 Cr | 100 Cr | 103 Cr | 108 Cr | 107 Cr |
| Profit before tax | 252 Cr | 477 Cr | 766 Cr | 843 Cr | 290 Cr | 635 Cr | 368 Cr | 128 Cr | 331 Cr | 392 Cr | 446 Cr | 404 Cr |
| Tax % | 34.0% | 36.4% | 31.3% | 37.2% | 31.5% | 30.0% | 24.6% | 48.6% | 29.1% | 27.6% | 18.4% | 23.5% |
| Net profit | 164 Cr | 301 Cr | 522 Cr | 523 Cr | 199 Cr | 445 Cr | 276 Cr | 64 Cr | 233 Cr | 281 Cr | 364 Cr | 307 Cr |
| EPS (₹) | ₹6.42 | ₹12.14 | ₹19.23 | ₹21.57 | ₹7.58 | ₹16.62 | ₹9.78 | ₹2.67 | ₹9.19 | ₹11.14 | ₹12.86 | ₹11.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,773 Cr | 4,649 Cr | 5,420 Cr | 5,830 Cr | 6,244 Cr | 7,705 Cr | 8,940 Cr | 9,646 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,024 Cr | 3,675 Cr | 3,813 Cr | 4,454 Cr | 5,318 Cr | 6,492 Cr | 7,326 Cr | 7,580 Cr | Sign in for TTM |
| EBITDA | 750 Cr | 974 Cr | 1,607 Cr | 1,376 Cr | 927 Cr | 1,213 Cr | 1,614 Cr | 2,067 Cr | Sign in for TTM |
| OPM % | 19.9% | 20.9% | 29.7% | 23.6% | 14.8% | 15.7% | 18.1% | 21.4% | Sign in for TTM |
| Other income | 58 Cr | 67 Cr | 63 Cr | 67 Cr | 126 Cr | 125 Cr | 93 Cr | 174 Cr | Sign in for TTM |
| Interest | 19 Cr | 17 Cr | 9 Cr | 8 Cr | 46 Cr | 138 Cr | 85 Cr | 76 Cr | Sign in for TTM |
| Depreciation | 182 Cr | 211 Cr | 209 Cr | 232 Cr | 262 Cr | 357 Cr | 398 Cr | 418 Cr | Sign in for TTM |
| Profit before tax | 548 Cr | 747 Cr | 1,389 Cr | 1,136 Cr | 745 Cr | 843 Cr | 1,131 Cr | 1,573 Cr | Sign in for TTM |
| Tax % | 19.0% | 18.1% | 17.3% | 19.7% | 34.0% | 37.2% | 30.4% | 24.2% | Sign in for TTM |
| Net profit | 442 Cr | 604 Cr | 1,141 Cr | 890 Cr | 479 Cr | 523 Cr | 785 Cr | 1,184 Cr | Sign in for TTM |
| EPS (₹) | ₹35.01 | ₹47.77 | ₹90.11 | ₹34.85 | ₹18.58 | ₹21.57 | ₹29.08 | ₹44.98 | Sign in for TTM |
| Dividend payout % | — | — | — | 11.4% | 21.2% | 9.7% | 12.9% | 4.4% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr |
| Reserves | 3,097 Cr | 3,602 Cr | 4,676 Cr | 5,467 Cr | 5,890 Cr | 6,307 Cr | 8,363 Cr | 8,031 Cr |
| Borrowings | 330 Cr | 388 Cr | 157 Cr | 761 Cr | 1,458 Cr | 1,388 Cr | 758 Cr | 595 Cr |
| Other liabilities | 991 Cr | 1,119 Cr | 1,101 Cr | 1,183 Cr | 1,254 Cr | 1,987 Cr | 2,614 Cr | 2,251 Cr |
| Total liabilities | 4,458 Cr | 5,185 Cr | 6,010 Cr | 7,467 Cr | 8,626 Cr | 11,101 Cr | 11,761 Cr | 12,370 Cr |
| Fixed assets (net) | 1,706 Cr | 1,799 Cr | 1,840 Cr | 2,057 Cr | 2,572 Cr | 4,340 Cr | 4,069 Cr | 4,441 Cr |
| CWIP | 36 Cr | 70 Cr | 181 Cr | 285 Cr | 122 Cr | 324 Cr | 616 Cr | 762 Cr |
| Investments | 322 Cr | 649 Cr | 868 Cr | 1,448 Cr | 496 Cr | 705 Cr | 789 Cr | 660 Cr |
| Other assets | 2,288 Cr | 2,715 Cr | 3,299 Cr | 4,188 Cr | 5,193 Cr | 5,545 Cr | 6,010 Cr | 6,423 Cr |
| Total assets | 4,458 Cr | 5,185 Cr | 6,010 Cr | 7,467 Cr | 8,626 Cr | 11,101 Cr | 11,761 Cr | 12,370 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 856 Cr | 806 Cr | 945 Cr | 1,321 Cr | 1,142 Cr |
| Cash from investing | — | — | — | -855 Cr | -725 Cr | -1,292 Cr | -869 Cr | -247 Cr |
| Cash from financing | — | — | — | 427 Cr | 507 Cr | -553 Cr | -283 Cr | -754 Cr |
| Net cash flow | — | — | — | 428 Cr | 588 Cr | -900 Cr | 169 Cr | 142 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 377 Cr | 311 Cr | 533 Cr | 546 Cr | 490 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.2% | 21.0% | 29.7% | 20.8% | 9.0% | 9.4% | 13.3% | 16.3% |
| ROE % | 14.2% | 16.7% | 24.2% | 16.1% | 8.0% | 7.1% | 8.8% | 12.0% |
| Debtor days | 63 | 70 | 55 | 55 | 58 | 80 | — | — |
| Inventory days | 350 | 323 | 355 | 398 | 371 | 407 | 409 | 424 |
| Days payable | 154 | 137 | 143 | 109 | 112 | 128 | — | — |
| Cash conversion cycle | 259 | 256 | 267 | 344 | 317 | 359 | 409 | 424 |
| Debt / equity | 0.11 | 0.00 | 0.03 | 0.14 | 0.25 | 0.22 | 0.09 | 0.06 |
| Current ratio | 2.25 | 2.18 | 3.08 | 3.12 | 2.87 | 2.35 | 2.50 | 2.76 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.97 | 0.37 | 0.08 |
Compare with peers
Loading peers…